Second-line therapy in advanced biliary tract cancer

What should be the standard?

Stefano Cereda, Carmen Belli, Alessia Rognone, Elena Mazza, Michele Reni

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Biliary tract cancer is a rare malignant tumor. Accordingly, to perform prospective and randomized trials is difficult and the knowledge of its natural history and optimal management remains limited. Chemotherapy is commonly used to improve the outcome and to delay tumor progression in advanced disease. Only recently, cisplatin-gemcitabine combination was identified as the new standard first-line therapy. Despite the outcome improvement, disease progression is a constant and approximately half of patients failing upfront treatment maintain a good performance status and are willing to undergo further treatment. No standard salvage chemotherapy regimen has been identified yet. Experiences of salvage therapy in advanced biliary tract cancer are sparse and yielded disappointing results. Well designed multi-institutional randomized trials are warranted to clarify the role and the activity of a second-line therapy.

Original languageEnglish
Pages (from-to)368-374
Number of pages7
JournalCritical Reviews in Oncology/Hematology
Volume88
Issue number2
DOIs
Publication statusPublished - Nov 2013

Fingerprint

Biliary Tract Neoplasms
gemcitabine
Drug Therapy
Salvage Therapy
Therapeutics
Natural History
Cisplatin
Disease Progression
Neoplasms

Keywords

  • Biliary tract cancer
  • Chemotherapy
  • Progressive disease
  • Salvage therapy
  • Second-line therapy

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Second-line therapy in advanced biliary tract cancer : What should be the standard? / Cereda, Stefano; Belli, Carmen; Rognone, Alessia; Mazza, Elena; Reni, Michele.

In: Critical Reviews in Oncology/Hematology, Vol. 88, No. 2, 11.2013, p. 368-374.

Research output: Contribution to journalArticle

Cereda, Stefano ; Belli, Carmen ; Rognone, Alessia ; Mazza, Elena ; Reni, Michele. / Second-line therapy in advanced biliary tract cancer : What should be the standard?. In: Critical Reviews in Oncology/Hematology. 2013 ; Vol. 88, No. 2. pp. 368-374.
@article{65f473a01f6a4aa5ab2aac5aad4ab4c6,
title = "Second-line therapy in advanced biliary tract cancer: What should be the standard?",
abstract = "Biliary tract cancer is a rare malignant tumor. Accordingly, to perform prospective and randomized trials is difficult and the knowledge of its natural history and optimal management remains limited. Chemotherapy is commonly used to improve the outcome and to delay tumor progression in advanced disease. Only recently, cisplatin-gemcitabine combination was identified as the new standard first-line therapy. Despite the outcome improvement, disease progression is a constant and approximately half of patients failing upfront treatment maintain a good performance status and are willing to undergo further treatment. No standard salvage chemotherapy regimen has been identified yet. Experiences of salvage therapy in advanced biliary tract cancer are sparse and yielded disappointing results. Well designed multi-institutional randomized trials are warranted to clarify the role and the activity of a second-line therapy.",
keywords = "Biliary tract cancer, Chemotherapy, Progressive disease, Salvage therapy, Second-line therapy",
author = "Stefano Cereda and Carmen Belli and Alessia Rognone and Elena Mazza and Michele Reni",
year = "2013",
month = "11",
doi = "10.1016/j.critrevonc.2013.05.010",
language = "English",
volume = "88",
pages = "368--374",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Second-line therapy in advanced biliary tract cancer

T2 - What should be the standard?

AU - Cereda, Stefano

AU - Belli, Carmen

AU - Rognone, Alessia

AU - Mazza, Elena

AU - Reni, Michele

PY - 2013/11

Y1 - 2013/11

N2 - Biliary tract cancer is a rare malignant tumor. Accordingly, to perform prospective and randomized trials is difficult and the knowledge of its natural history and optimal management remains limited. Chemotherapy is commonly used to improve the outcome and to delay tumor progression in advanced disease. Only recently, cisplatin-gemcitabine combination was identified as the new standard first-line therapy. Despite the outcome improvement, disease progression is a constant and approximately half of patients failing upfront treatment maintain a good performance status and are willing to undergo further treatment. No standard salvage chemotherapy regimen has been identified yet. Experiences of salvage therapy in advanced biliary tract cancer are sparse and yielded disappointing results. Well designed multi-institutional randomized trials are warranted to clarify the role and the activity of a second-line therapy.

AB - Biliary tract cancer is a rare malignant tumor. Accordingly, to perform prospective and randomized trials is difficult and the knowledge of its natural history and optimal management remains limited. Chemotherapy is commonly used to improve the outcome and to delay tumor progression in advanced disease. Only recently, cisplatin-gemcitabine combination was identified as the new standard first-line therapy. Despite the outcome improvement, disease progression is a constant and approximately half of patients failing upfront treatment maintain a good performance status and are willing to undergo further treatment. No standard salvage chemotherapy regimen has been identified yet. Experiences of salvage therapy in advanced biliary tract cancer are sparse and yielded disappointing results. Well designed multi-institutional randomized trials are warranted to clarify the role and the activity of a second-line therapy.

KW - Biliary tract cancer

KW - Chemotherapy

KW - Progressive disease

KW - Salvage therapy

KW - Second-line therapy

UR - http://www.scopus.com/inward/record.url?scp=84885844811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885844811&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2013.05.010

DO - 10.1016/j.critrevonc.2013.05.010

M3 - Article

VL - 88

SP - 368

EP - 374

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 2

ER -